Alzheimer’s Drugs Market
Alzheimer’s Drugs Market (Drug class - Cholinergic, Memantine, and Combined Drug; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Press Release :
Global Alzheimer’s Drugs Market – An Overview:
The global Alzheimer’s drugs market is set to grow over the forecast period of 2017 to 2025, owing to multiple factors, as per Transparency Market Research. It notes that due to increase in incidence of this progressive degenerative disorder of the brain, demand for these drugs would grow, helping the market chart a compound annual growth rate (CAGR) of 7.5%. This will take the market worth up to USD 6.4 billion by the end of the states period, which is the assessment period of the global Alzheimer’s drugs market report.
An extremely common factor of dementia, Alzheimer’s interferes with a patient’s ability to think coherently, often starting with a problem with remembering conversations and enlarging as a challenge in behavioral skills. It is significant to note here that a number of environmental factors are driving up cases if this disease. Factors of growth also include certain genetic traits and lifestyle choices. Western countries demonstrate a high number of these cases.
Here, prevalence of neurodegenerative diseases deserves a mention. It is growing rapidly, leading to players in the Alzheimer’s drugs market towards a more proactive approach to drug discovery and development. This is creating a robust drug pipeline and promises the market notable growth in the future, particularly over the forecast period.
It is also quite significant to note here that the vendor landscape of the market is consolidated and is witnessing intense activity directed towards growth. Some of the top players that are driving the market forward with their proactive strategies – organic and inorganic – are Allergan plc and Novartis AG. Other leading companies include Johnson and Johnson, Ono Pharmaceutical Co Ltd., Merz Holding GmBH & Co KG, Daiichi Sankyo Company Ltd, and Eisai Co Ltd., among others.
Some of the top strategies that are often noted in the global Alzheimer’s drugs market include key alliances such as mergers and acquisitions and partnerships and collaborations – based on mutual synergies. These strategic maneuvers often pave way for growth in the future by providing players with better control over market share. Combination of resources such as labor and technology are usually crucial for market players to create dominance in the market.
Research and development (R&D) and technological advancement hold prominence in the market landscape owing to massive reliance on effective drug discovery and development. These are therefore considered key determinants of growth in the global Alzheimer’s drugs market over the forecast period.
Memantine Segment to Contribute Massively to Growth in Alzheimer’s Drugs Market over the Forecast Period
Drug class, region, and distribution channels are the broad categories on the basis of which this report has been segmented. Sub-segments in the drug class category are Cholinergic, Combined Drug, and Memantine. In terms of distribution channels, there is online sales, and offline sales – retail pharmacy and hospital pharmacy.
Memantine from the first segment will dominate the market over the forecast period. The report states that it has a major sway in the market. Few options available in the market is the reason that it is set to propel growth in the global Alzheimer’s drugs market. It is also worth noting here that a number of patent expirations are at the helm and these would also help growth in the segment, propelling the market on a high growth trajectory. This along with combination of limited drugs is set to pave way for the market to witness increased revenues over the forecast period.
Additionally, there is another segment that will keep market players hooked to the landscape. The segment is that of cholinergic. Over the forecast period, it will show a tremendous growth curve. This growth that the segment is anticipated to record will be an outcome of non-availability of other effective drugs.
North America to be the Dominant Region in the Global Alzheimer’s Drugs Market over the Forecast Period
The global Alzheimer’s drugs market report is a comprehensive study, incorporating a granular regional analysis. The report, prepared by Transparency Market Research, covers key regions of the world to provide a deep-dive into threats, opportunities, strengths and weaknesses of these regions. The list includes Latin America, Middle East and Africa, Europe, North America, and Asia Pacific.
Of these, North America would emerge as a lucrative market, continuing to hold its dominance over the global Alzheimer’s drugs market share. Reasons that support this growth is a robust healthcare infrastructure and a healthy research and development of environment. Others include presence of strong pharmaceutical players, a large number of whom also have a keen eye on this market. A large number of cases of Alzheimer’s are also a significant growth propeller in the market. High level of awareness about the disease and a rapidly ageing population is also supporting growth in the market. By 2050, one in every four people will be aged 65 and above in both Europe as well as North America.
By the year 2025, North America is said to reach a steep valuation of about USD 3 billion – a notable rise from USD 1.7 billion that was noted in the year of 2017. This also translates to a CAGR (Compound Annual Growth Rate) of 8.6% over the forecast period.
New opportunities will also arise in regions such as Latin America and Asia Pacific over the forecast period, notes Transparency Market Research. Government efforts towards improving research and towards improving healthcare outcomes are also a notable growth factor in the Asia Pacific region.
Increasing Neurological Disorders in Geriatric Population to Benefit Global Alzheimer’s Drugs Market
Alzheimer's disease is the most common type of dementia and a progressive neurological disease. Symptoms comprise the deterioration of reasoning skills and memory loss, as well as problems in speech and problem-solving. Alzheimer's disease signs appear gradually over several years and gradually become more serious. The growth of the global Alzheimer’s drugs market is being driven by the expanding ageing population and increasing occurrence of neurological disorders in the geriatric community around the world. Besides that, increasing understanding of Alzheimer's disease treatment global is likely to boost overall demand for Alzheimer's drugs in the years to come.
In accordance to the WHO (World Health Organization), about 50 million individuals suffer from dementia, a widespread manifestation of Alzheimer's disease, with 10 million new cases diagnosed each year. These diseases are also highly prevalent and often lead to the development of these medicines. As a result, the rising incidence of the neurological diseases in the geriatric population around the world is likely to propel the global Alzheimer's drugs market forward.
Increasing Awareness about the Disease to Trigger Growth of the Market
Globally, consumers are becoming more aware of the treatment options for Alzheimer's disease, which is propelling the market forward. Furthermore, consumers are becoming more aware of the many new care choices, which is fueling the rise of the global Alzheimer's drugs market. The challenge in detecting early signs of Alzheimer's disease is posing a threat to the market's expansion. Furthermore, the high cost of research and development activities for drug discovery is further likely to limiting the market's expansion.
The occurrence of Alzheimer's disease is expected to rise across the globe, as is the ageing populace. The global ageing population is expected to increase the prevalence of Alzheimer's disease in the years to come.
A more and more people are being diagnosed with Alzheimer's disease, necessitating the development of new treatment methods. As a result, there are several competitors with treatment medications in various phases of clinical trials. The global Alzheimer's drug market is predicted to be driven by a robust pharmaceutical pipeline. The main players are concentrating on the development of novel treatments to help avoid, delay, or slow progression of the disease and better the symptoms of Alzheimer's. If the onset of the disease could successfully be postponed by 5 years, it is projected that the average prevalence of the disease will be reduced by almost half.
Global Alzheimer’s Drugs Market: Overview
This report on the Alzheimer’s drugs market analyzes the current and future scenario of the global market. Increasing prevalence of Alzheimer’s, innovation in the development of new drugs, biomarker analysis and most promising molecules analysis, drug class sales during the forecast period.
Global Alzheimer’s Drugs Market: Research Methodology
The global Alzheimer’s drugs market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country’s market with respect to the segments based on drug class type, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises PEST Analysis, Porters Five Forces Analysis and Pipeline Analysis to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Alzheimer’s drug market.
Global Alzheimer’s Drugs Market: Segmentation
Based on drug class, the market has been segmented into four major drug class such as cholinergic, memantine, combined drugs, and others. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
As per distribution channels, the global Alzheimer’s drugs market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online sales. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of Alzheimer’s are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Geographically, Alzheimer’s drugs market on the basis of region has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
Global Alzheimer’s Drugs Market: Competitive Dynamics
The report also profiles major key players in the Alzheimer’s drugs market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis. Major players operating in the Alzheimer’s drug market included in this report are Allergan plc, Novartis AG, Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.
Global Alzheimer’s Drugs Market is segmented as below:
by Drug Class
by Distribution Channel